Please login to the form below

Not currently logged in
Email:
Password:

UCB appoints new board members

Brussels-based biopharmaceutical company, UCB, has announced Bert De Graeve and Alexandre Van Damme as candidates for the Board

Brussels-based biopharmaceutical company, UCB, has announced Bert De Graeve and Alexandre Van Damme as candidates to join the Board at the company's general assembly on April 29.  After three terms on the Board, Prince Lorenz will step down at the forthcoming assembly. UCB's Board of Directors and Executive Committee thanked him for his contributions.

Bert De Graeve is chief executive officer of the Bekaert Group. He is also a member of the International Business Leaders' Advisory Council for the Mayor of Shanghai (IBLAC), president of the Flanders-China Chamber of Commerce, member of the advisory board of the Conference Board China Centre for Economics and Business in Beijing, member of the Board of the Concours Reine Elisabeth and senior member of the Conference Board New York.

Alexandre Van Damme is on the boards of Anheuser-Busch InBev and InBev-Baillet Latour (not-for-profit organisation). He is also a member of the INSEAD International Council and the Solvay Business School Consultative Council. Their appointments will broaden the skills of the Board. Following approval at the general assembly, the new Board will have eight independent members; Armand De Decker, Bert De Graeve, Peter Fellner, Jean-Pierre Kinet, Thomas Leysen, Tom McKillop, Gerhard Mayr, and Norman Ornstein.

The remaining members include Karel Boone, chairman, Evelyn du Monceau, vice chair, Roch Doliveux, executive director, Arnoud de Pret, Bridget van Rijckevorsel, Alexandre Van Damme and Gaëtan van de Werve. 

29th March 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics